Bakhtiyari-Ramezani Mahdiyeh, Nasiri Meysam, Baniasadi Mansoureh
Plasma Physics and Nuclear Fusion Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
Department of Cellular and Molecular Biology, School of Biology, Damghan University, Damghan, Iran.
Sci Rep. 2025 Mar 27;15(1):10569. doi: 10.1038/s41598-025-95065-z.
Nowadays, cold atmospheric plasma (CAP) technology has developed as an innovative tool for cancer therapy. Although many studies have reported the antitumor effects of plasma in vivo and in vitro, there are many challenges, including standardization of plasma devices and treatment time for different tumors. For the first time, we aimed to evaluate and compare optimal exposure time and direction-dependent cellular effects of helium and argon plasma on the 4T1 cancer cells and a triple-negative mouse model of breast cancer. This study used two types of helium and argon plasma jet devices with different input parameters. In vitro evaluations on 4T1 cell line using the MTT assays and flow cytometry analysis demonstrate CAP-induced apoptosis in all treated groups, especially in the direct approach. These changes were concurrent with increased intracellular reactive oxygen species levels and decreased total antioxidant capacity in these cells. In vivo studies concurrent with in vitro results revealed that CAP therapy reduces tumor size, decreases Nottingham histological score, prevents weight loss, and increases the survival rate in all treated groups. These results suggest that plasma therapy may overcome the adverse effects of approved cancer therapeutic strategies and seems to be a significant issue for cancer patients in the clinical stage, alone or in combination with current therapeutic programs.
如今，冷大气等离子体（CAP）技术已发展成为一种用于癌症治疗的创新工具。尽管许多研究报告了等离子体在体内和体外的抗肿瘤作用，但仍存在许多挑战，包括等离子体设备的标准化以及针对不同肿瘤的治疗时间。我们首次旨在评估和比较氦气和氩气等离子体对4T1癌细胞和三阴性乳腺癌小鼠模型的最佳暴露时间及方向依赖性细胞效应。本研究使用了两种具有不同输入参数的氦气和氩气等离子体射流设备。使用MTT法和流式细胞术分析对4T1细胞系进行的体外评估表明，CAP诱导所有处理组细胞凋亡，尤其是直接处理方式。这些变化与这些细胞内活性氧水平升高和总抗氧化能力降低同时发生。与体外结果一致的体内研究表明，CAP疗法可减小肿瘤大小、降低诺丁汉组织学评分、防止体重减轻并提高所有处理组的存活率。这些结果表明，等离子体疗法可能克服已批准的癌症治疗策略的不良反应，并且对于临床阶段的癌症患者而言，单独或与当前治疗方案联合使用似乎都是一个重要问题。
